CS238609B2 - Production method of new derivatives cis-phenyl-1,2,3,4-tetrahydro-1-naphthalene-amines - Google Patents
Production method of new derivatives cis-phenyl-1,2,3,4-tetrahydro-1-naphthalene-amines Download PDFInfo
- Publication number
- CS238609B2 CS238609B2 CS807314A CS731480A CS238609B2 CS 238609 B2 CS238609 B2 CS 238609B2 CS 807314 A CS807314 A CS 807314A CS 731480 A CS731480 A CS 731480A CS 238609 B2 CS238609 B2 CS 238609B2
- Authority
- CS
- Czechoslovakia
- Prior art keywords
- cis
- formula
- tetrahydro
- solution
- phenyl
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 62
- 150000003839 salts Chemical class 0.000 claims abstract description 20
- 239000002253 acid Substances 0.000 claims abstract description 15
- 239000000203 mixture Substances 0.000 claims description 45
- 229910052739 hydrogen Inorganic materials 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 25
- 239000001257 hydrogen Substances 0.000 claims description 11
- 229910052731 fluorine Inorganic materials 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 150000001412 amines Chemical class 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- 239000003377 acid catalyst Substances 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract description 30
- 229940076279 serotonin Drugs 0.000 abstract description 13
- 239000000935 antidepressant agent Substances 0.000 abstract description 11
- IWNWWVPLTTUPBQ-UHFFFAOYSA-N 4-phenyl-1,2,3,4-tetrahydronaphthalen-1-amine Chemical class C12=CC=CC=C2C(N)CCC1C1=CC=CC=C1 IWNWWVPLTTUPBQ-UHFFFAOYSA-N 0.000 abstract description 2
- 230000005856 abnormality Effects 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 78
- 239000000243 solution Substances 0.000 description 61
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 51
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 42
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 39
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 27
- 239000011541 reaction mixture Substances 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 20
- 239000000126 substance Substances 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 239000000047 product Substances 0.000 description 15
- 239000007788 liquid Substances 0.000 description 13
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 13
- 235000019341 magnesium sulphate Nutrition 0.000 description 13
- 239000007787 solid Substances 0.000 description 13
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 12
- 229920006395 saturated elastomer Polymers 0.000 description 12
- -1 norepinephrine Chemical compound 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 11
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 10
- 229940005513 antidepressants Drugs 0.000 description 10
- 229910052757 nitrogen Inorganic materials 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- 238000010992 reflux Methods 0.000 description 9
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 239000003054 catalyst Substances 0.000 description 8
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 7
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 7
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 7
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 7
- 229960002748 norepinephrine Drugs 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 229960003638 dopamine Drugs 0.000 description 6
- 239000012259 ether extract Substances 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- 238000002844 melting Methods 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 5
- 208000020401 Depressive disease Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 206010044565 Tremor Diseases 0.000 description 5
- 239000000908 ammonium hydroxide Substances 0.000 description 5
- 230000001430 anti-depressive effect Effects 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 4
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 102000001435 Synapsin Human genes 0.000 description 4
- 108050009621 Synapsin Proteins 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 4
- 239000000538 analytical sample Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- 201000003102 mental depression Diseases 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 4
- 229960003147 reserpine Drugs 0.000 description 4
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 4
- 230000013275 serotonin uptake Effects 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 3
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 3
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- DKMROQRQHGEIOW-UHFFFAOYSA-N Diethyl succinate Chemical compound CCOC(=O)CCC(=O)OCC DKMROQRQHGEIOW-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 239000006286 aqueous extract Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003610 charcoal Substances 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 210000001653 corpus striatum Anatomy 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000002024 ethyl acetate extract Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 150000003840 hydrochlorides Chemical class 0.000 description 3
- 210000003016 hypothalamus Anatomy 0.000 description 3
- 239000008247 solid mixture Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 210000000225 synapse Anatomy 0.000 description 3
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 3
- DQUHBUPSCAWERK-UHFFFAOYSA-N 1-(4-methoxyphenyl)-1,2,3,4-tetrahydronaphthalene Chemical compound C1=CC(OC)=CC=C1C1C2=CC=CC=C2CCC1 DQUHBUPSCAWERK-UHFFFAOYSA-N 0.000 description 2
- KITYLYRCUBYTCO-UHFFFAOYSA-N 1-(4-methoxyphenyl)-3,4-dihydro-2h-naphthalen-1-ol Chemical compound C1=CC(OC)=CC=C1C1(O)C2=CC=CC=C2CCC1 KITYLYRCUBYTCO-UHFFFAOYSA-N 0.000 description 2
- RUFPHBVGCFYCNW-UHFFFAOYSA-N 1-naphthylamine Chemical class C1=CC=C2C(N)=CC=CC2=C1 RUFPHBVGCFYCNW-UHFFFAOYSA-N 0.000 description 2
- XHLHPRDBBAGVEG-UHFFFAOYSA-N 1-tetralone Chemical compound C1=CC=C2C(=O)CCCC2=C1 XHLHPRDBBAGVEG-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- WMRZQZSHORKWBP-UHFFFAOYSA-N 3-ethoxycarbonyl-4-(4-fluorophenyl)-4-phenylbut-3-enoic acid Chemical compound C=1C=C(F)C=CC=1C(=C(CC(O)=O)C(=O)OCC)C1=CC=CC=C1 WMRZQZSHORKWBP-UHFFFAOYSA-N 0.000 description 2
- JGMBHJNMQVKDMW-UHFFFAOYSA-N 4-(3,4-dichlorophenyl)-3,4-dihydro-2h-naphthalen-1-one Chemical compound C1=C(Cl)C(Cl)=CC=C1C1C2=CC=CC=C2C(=O)CC1 JGMBHJNMQVKDMW-UHFFFAOYSA-N 0.000 description 2
- ZBLZQVJTLMFDCG-UHFFFAOYSA-N 4-(3,4-dichlorophenyl)-4-phenylbutanoic acid Chemical compound C=1C=C(Cl)C(Cl)=CC=1C(CCC(=O)O)C1=CC=CC=C1 ZBLZQVJTLMFDCG-UHFFFAOYSA-N 0.000 description 2
- FHRXAVHXIKEWEU-UHFFFAOYSA-N 4-(4-methoxyphenyl)-1,2-dihydronaphthalene Chemical compound C1=CC(OC)=CC=C1C1=CCCC2=CC=CC=C12 FHRXAVHXIKEWEU-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002262 Schiff base Substances 0.000 description 2
- 150000004753 Schiff bases Chemical class 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000012965 benzophenone Substances 0.000 description 2
- 150000008366 benzophenones Chemical class 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000012059 conventional drug carrier Substances 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical class I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 230000002631 hypothermal effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- LPNBBFKOUUSUDB-UHFFFAOYSA-N p-toluic acid Chemical compound CC1=CC=C(C(O)=O)C=C1 LPNBBFKOUUSUDB-UHFFFAOYSA-N 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 239000000123 paper Substances 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- OHTYZZYAMUVKQS-UHFFFAOYSA-N phenyl-[4-(trifluoromethyl)phenyl]methanone Chemical compound C1=CC(C(F)(F)F)=CC=C1C(=O)C1=CC=CC=C1 OHTYZZYAMUVKQS-UHFFFAOYSA-N 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000001242 postsynaptic effect Effects 0.000 description 2
- 239000012286 potassium permanganate Substances 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 230000003518 presynaptic effect Effects 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- WLJRSPZEWYZFIZ-RVFRADKHSA-N (1R)-4-(2,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine hydrochloride Chemical compound Cl.CN[C@@H]1CCC(C2=C(Cl)C=C(Cl)C=C2)C2=C1C=CC=C2 WLJRSPZEWYZFIZ-RVFRADKHSA-N 0.000 description 1
- BLFQGGGGFNSJKA-UQICWFIISA-N (1r)-4-(3,4-dichlorophenyl)-n-methyl-1,2,3,4-tetrahydronaphthalen-1-amine;hydrochloride Chemical compound Cl.C([C@H](C1=CC=CC=C11)NC)CC1C1=CC=C(Cl)C(Cl)=C1 BLFQGGGGFNSJKA-UQICWFIISA-N 0.000 description 1
- JEFAHXOMQYOJGI-JZABEEBUSA-N (1r)-7-chloro-4-(4-chlorophenyl)-n-methyl-1,2,3,4-tetrahydronaphthalen-1-amine;hydrochloride Chemical compound Cl.C([C@H](C1=CC(Cl)=CC=C11)NC)CC1C1=CC=C(Cl)C=C1 JEFAHXOMQYOJGI-JZABEEBUSA-N 0.000 description 1
- XTSOELQVDLSJFM-JZABEEBUSA-N (1r)-n-methyl-4-phenyl-1,2,3,4-tetrahydronaphthalen-1-amine;hydrochloride Chemical compound Cl.C([C@H](C1=CC=CC=C11)NC)CC1C1=CC=CC=C1 XTSOELQVDLSJFM-JZABEEBUSA-N 0.000 description 1
- IWNWWVPLTTUPBQ-XJKSGUPXSA-N (1r,4s)-4-phenyl-1,2,3,4-tetrahydronaphthalen-1-amine Chemical class C1([C@@H]2CC[C@H](C3=CC=CC=C32)N)=CC=CC=C1 IWNWWVPLTTUPBQ-XJKSGUPXSA-N 0.000 description 1
- NVXPZMLRGBVYQV-WMLDXEAASA-N (1r,4s)-n-methyl-4-phenyl-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1([C@@H]2CC[C@H](C3=CC=CC=C32)NC)=CC=CC=C1 NVXPZMLRGBVYQV-WMLDXEAASA-N 0.000 description 1
- VLTYTTRXESKBKI-UHFFFAOYSA-N (2,4-dichlorophenyl)-phenylmethanone Chemical compound ClC1=CC(Cl)=CC=C1C(=O)C1=CC=CC=C1 VLTYTTRXESKBKI-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical class O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- LLUPHTAYNHAVQT-UHFFFAOYSA-N (3,4-dichlorophenyl)-phenylmethanone Chemical compound C1=C(Cl)C(Cl)=CC=C1C(=O)C1=CC=CC=C1 LLUPHTAYNHAVQT-UHFFFAOYSA-N 0.000 description 1
- KEOLYBMGRQYQTN-UHFFFAOYSA-N (4-bromophenyl)-phenylmethanone Chemical compound C1=CC(Br)=CC=C1C(=O)C1=CC=CC=C1 KEOLYBMGRQYQTN-UHFFFAOYSA-N 0.000 description 1
- OGTSHGYHILFRHD-UHFFFAOYSA-N (4-fluorophenyl)-phenylmethanone Chemical compound C1=CC(F)=CC=C1C(=O)C1=CC=CC=C1 OGTSHGYHILFRHD-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-SSDOTTSWSA-N (R)-mandelic acid Chemical compound OC(=O)[C@H](O)C1=CC=CC=C1 IWYDHOAUDWTVEP-SSDOTTSWSA-N 0.000 description 1
- KBEGDFHMVUHUBZ-UHFFFAOYSA-N 1-(4-methoxyphenyl)-4-(methylamino)-3,4-dihydro-2h-naphthalen-1-ol Chemical compound C12=CC=CC=C2C(NC)CCC1(O)C1=CC=C(OC)C=C1 KBEGDFHMVUHUBZ-UHFFFAOYSA-N 0.000 description 1
- HTDQSWDEWGSAMN-UHFFFAOYSA-N 1-bromo-2-methoxybenzene Chemical compound COC1=CC=CC=C1Br HTDQSWDEWGSAMN-UHFFFAOYSA-N 0.000 description 1
- NHDODQWIKUYWMW-UHFFFAOYSA-N 1-bromo-4-chlorobenzene Chemical compound ClC1=CC=C(Br)C=C1 NHDODQWIKUYWMW-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- KWVPFECTOKLOBL-KTKRTIGZSA-N 2-[(z)-octadec-9-enoxy]ethanol Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCO KWVPFECTOKLOBL-KTKRTIGZSA-N 0.000 description 1
- RZPFVRFSYMUDJO-UHFFFAOYSA-N 2h-naphthalen-1-one Chemical compound C1=CC=C2C(=O)CC=CC2=C1 RZPFVRFSYMUDJO-UHFFFAOYSA-N 0.000 description 1
- VTXNOVCTHUBABW-UHFFFAOYSA-N 3,4-dichlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Cl)C(Cl)=C1 VTXNOVCTHUBABW-UHFFFAOYSA-N 0.000 description 1
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- OKISUZLXOYGIFP-UHFFFAOYSA-N 4,4'-dichlorobenzophenone Chemical compound C1=CC(Cl)=CC=C1C(=O)C1=CC=C(Cl)C=C1 OKISUZLXOYGIFP-UHFFFAOYSA-N 0.000 description 1
- CCUBHTFLNYYIES-UHFFFAOYSA-N 4,4-bis(4-chlorophenyl)butanoic acid Chemical compound C=1C=C(Cl)C=CC=1C(CCC(=O)O)C1=CC=C(Cl)C=C1 CCUBHTFLNYYIES-UHFFFAOYSA-N 0.000 description 1
- PVNAVSKAAHRGRJ-UHFFFAOYSA-N 4-(2-fluorophenyl)-4-phenylbut-3-enoic acid Chemical compound C=1C=CC=C(F)C=1C(=CCC(=O)O)C1=CC=CC=C1 PVNAVSKAAHRGRJ-UHFFFAOYSA-N 0.000 description 1
- IOQHRBSCAXDTNE-UHFFFAOYSA-N 4-(3,4-dichlorophenyl)-3-ethoxycarbonyl-4-phenylbut-3-enoic acid Chemical compound C=1C=C(Cl)C(Cl)=CC=1C(=C(CC(O)=O)C(=O)OCC)C1=CC=CC=C1 IOQHRBSCAXDTNE-UHFFFAOYSA-N 0.000 description 1
- SBSRZRLDJSBWQH-UHFFFAOYSA-N 4-(3,4-dichlorophenyl)-4-phenylbut-3-enoic acid Chemical compound C=1C=C(Cl)C(Cl)=CC=1C(=CCC(=O)O)C1=CC=CC=C1 SBSRZRLDJSBWQH-UHFFFAOYSA-N 0.000 description 1
- BLFQGGGGFNSJKA-UHFFFAOYSA-N 4-(3,4-dichlorophenyl)-n-methyl-1,2,3,4-tetrahydronaphthalen-1-amine;hydron;chloride Chemical compound Cl.C12=CC=CC=C2C(NC)CCC1C1=CC=C(Cl)C(Cl)=C1 BLFQGGGGFNSJKA-UHFFFAOYSA-N 0.000 description 1
- OIEBOOCWMVDAJZ-UHFFFAOYSA-N 4-(4-bromophenyl)-4-phenylbut-3-enoic acid Chemical compound C=1C=C(Br)C=CC=1C(=CCC(=O)O)C1=CC=CC=C1 OIEBOOCWMVDAJZ-UHFFFAOYSA-N 0.000 description 1
- ZEIGNLYJYUTFQX-UHFFFAOYSA-N 4-(4-bromophenyl)-4-phenylbutanoic acid Chemical compound C=1C=C(Br)C=CC=1C(CCC(=O)O)C1=CC=CC=C1 ZEIGNLYJYUTFQX-UHFFFAOYSA-N 0.000 description 1
- AEVYFDPJZXKWPI-UHFFFAOYSA-N 4-(4-fluorophenyl)-4-phenylbut-3-enoic acid Chemical compound C=1C=C(F)C=CC=1C(=CCC(=O)O)C1=CC=CC=C1 AEVYFDPJZXKWPI-UHFFFAOYSA-N 0.000 description 1
- ZGTVFDARSVHBEF-UHFFFAOYSA-N 4-(4-fluorophenyl)-4-phenylbutanoic acid Chemical compound C=1C=C(F)C=CC=1C(CCC(=O)O)C1=CC=CC=C1 ZGTVFDARSVHBEF-UHFFFAOYSA-N 0.000 description 1
- DVKZCJSFZWEOFW-UHFFFAOYSA-N 4-(4-methoxyphenyl)-n-methyl-1,2-dihydronaphthalen-1-amine;hydrochloride Chemical compound Cl.C12=CC=CC=C2C(NC)CC=C1C1=CC=C(OC)C=C1 DVKZCJSFZWEOFW-UHFFFAOYSA-N 0.000 description 1
- DRNJIKRLQJRKMM-UHFFFAOYSA-N 4-(trifluoromethyl)benzonitrile Chemical compound FC(F)(F)C1=CC=C(C#N)C=C1 DRNJIKRLQJRKMM-UHFFFAOYSA-N 0.000 description 1
- SEVMQEIGENUPIE-UHFFFAOYSA-N 4-bromo-1-fluoro-2-methoxybenzene Chemical compound COC1=CC(Br)=CC=C1F SEVMQEIGENUPIE-UHFFFAOYSA-N 0.000 description 1
- DWNXGZBXFDNKOR-UHFFFAOYSA-N 4-bromo-2-fluoro-1-methoxybenzene Chemical compound COC1=CC=C(Br)C=C1F DWNXGZBXFDNKOR-UHFFFAOYSA-N 0.000 description 1
- QJPJQTDYNZXKQF-UHFFFAOYSA-N 4-bromoanisole Chemical compound COC1=CC=C(Br)C=C1 QJPJQTDYNZXKQF-UHFFFAOYSA-N 0.000 description 1
- UGVRJVHOJNYEHR-UHFFFAOYSA-N 4-chlorobenzophenone Chemical compound C1=CC(Cl)=CC=C1C(=O)C1=CC=CC=C1 UGVRJVHOJNYEHR-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- FXQHMVSYDKTZRJ-UHFFFAOYSA-N 4-hydroxy-4-(4-methoxyphenyl)-2,3-dihydronaphthalen-1-one Chemical compound C1=CC(OC)=CC=C1C1(O)C2=CC=CC=C2C(=O)CC1 FXQHMVSYDKTZRJ-UHFFFAOYSA-N 0.000 description 1
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 1
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 1
- 229940000681 5-hydroxytryptophan Drugs 0.000 description 1
- 206010002942 Apathy Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 101100294102 Caenorhabditis elegans nhr-2 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- IAXNFPNHCGAXIW-RUMBQWAVSA-N Cl.CN[C@@H]1CCC(C2=CC=CC=C12)C1=CC=C(C=C1)OC Chemical compound Cl.CN[C@@H]1CCC(C2=CC=CC=C12)C1=CC=C(C=C1)OC IAXNFPNHCGAXIW-RUMBQWAVSA-N 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical class [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- IMNFDUFMRHMDMM-UHFFFAOYSA-N anhydrous n-heptane Natural products CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 239000003420 antiserotonin agent Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 150000004648 butanoic acid derivatives Chemical class 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- QSKWJTXWJJOJFP-UHFFFAOYSA-N chloroform;ethoxyethane Chemical compound ClC(Cl)Cl.CCOCC QSKWJTXWJJOJFP-UHFFFAOYSA-N 0.000 description 1
- 125000000068 chlorophenyl group Chemical group 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
- 229960004038 fluvoxamine Drugs 0.000 description 1
- 239000010200 folin Substances 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000013284 inhibition of norepinephrine uptake Effects 0.000 description 1
- 230000008517 inhibition of serotonin uptake Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229950009215 phenylbutanoic acid Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000001967 plate count agar Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000037047 psychomotor activity Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 150000003900 succinic acid esters Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 230000018405 transmission of nerve impulse Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/04—Preparation of compounds containing amino groups bound to a carbon skeleton by substitution of functional groups by amino groups
- C07C209/14—Preparation of compounds containing amino groups bound to a carbon skeleton by substitution of functional groups by amino groups by substitution of hydroxy groups or of etherified or esterified hydroxy groups
- C07C209/16—Preparation of compounds containing amino groups bound to a carbon skeleton by substitution of functional groups by amino groups by substitution of hydroxy groups or of etherified or esterified hydroxy groups with formation of amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/21—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing rings other than six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/30—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by two rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/004—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reaction with organometalhalides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
- C07C45/28—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of CHx-moieties
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
- C07C45/46—Friedel-Crafts reactions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/687—Unsaturated compounds containing a keto groups being part of a ring containing halogen
- C07C49/697—Unsaturated compounds containing a keto groups being part of a ring containing halogen containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
- C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
- C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
- C07C57/60—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings having unsaturation outside the rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CS818297A CS238617B2 (en) | 1979-11-01 | 1981-11-11 | Preparation method of new derivatives of cis-phenyl-1,2,3,4-tetra-hydro-1-naphtaleneamines |
| CS818298A CS238618B2 (en) | 1979-11-01 | 1981-11-11 | Production method of new derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphtalenamines |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/090,240 US4536518A (en) | 1979-11-01 | 1979-11-01 | Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CS238609B2 true CS238609B2 (en) | 1985-12-16 |
Family
ID=22221931
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CS807314A CS238609B2 (en) | 1979-11-01 | 1980-10-29 | Production method of new derivatives cis-phenyl-1,2,3,4-tetrahydro-1-naphthalene-amines |
| CS818297A CS238617B2 (en) | 1979-11-01 | 1981-11-11 | Preparation method of new derivatives of cis-phenyl-1,2,3,4-tetra-hydro-1-naphtaleneamines |
| CS818298A CS238618B2 (en) | 1979-11-01 | 1981-11-11 | Production method of new derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphtalenamines |
| CS913542A CS354291A3 (en) | 1979-11-01 | 1991-11-22 | Cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives withanti-depressive activity |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CS818297A CS238617B2 (en) | 1979-11-01 | 1981-11-11 | Preparation method of new derivatives of cis-phenyl-1,2,3,4-tetra-hydro-1-naphtaleneamines |
| CS818298A CS238618B2 (en) | 1979-11-01 | 1981-11-11 | Production method of new derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphtalenamines |
| CS913542A CS354291A3 (en) | 1979-11-01 | 1991-11-22 | Cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives withanti-depressive activity |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US4536518A (bs) |
| EP (1) | EP0030081B1 (bs) |
| JP (1) | JPS605584B2 (bs) |
| KR (2) | KR840002001B1 (bs) |
| AT (1) | ATE2668T1 (bs) |
| AU (1) | AU517357B2 (bs) |
| BA (2) | BA97149B1 (bs) |
| BG (1) | BG60333B2 (bs) |
| CA (1) | CA1130815A (bs) |
| CS (4) | CS238609B2 (bs) |
| DD (2) | DD155615A5 (bs) |
| DE (2) | DE3062225D1 (bs) |
| DK (1) | DK153390C (bs) |
| EG (1) | EG15527A (bs) |
| ES (2) | ES496443A0 (bs) |
| FI (1) | FI68806C (bs) |
| GR (1) | GR70781B (bs) |
| HK (1) | HK82284A (bs) |
| HR (2) | HRP930199B1 (bs) |
| HU (1) | HU182224B (bs) |
| IE (1) | IE50395B1 (bs) |
| IL (1) | IL61374A (bs) |
| IN (2) | IN159643B (bs) |
| LU (1) | LU88330I2 (bs) |
| LV (2) | LV5457A3 (bs) |
| MX (1) | MX5980E (bs) |
| MY (1) | MY8500326A (bs) |
| NL (1) | NL940018I1 (bs) |
| NO (2) | NO148996C (bs) |
| NZ (1) | NZ195407A (bs) |
| PH (1) | PH17319A (bs) |
| PT (1) | PT72004B (bs) |
| SG (1) | SG56584G (bs) |
| SI (2) | SI8012798A8 (bs) |
| SU (2) | SU1014467A3 (bs) |
| UA (2) | UA6301A1 (bs) |
| YU (2) | YU41951B (bs) |
| ZA (1) | ZA806726B (bs) |
Families Citing this family (172)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8004002L (sv) * | 1980-05-29 | 1981-11-30 | Arvidsson Folke Lars Erik | Terapeutiskt anvendbara tetralinderivat |
| US4839104A (en) * | 1987-06-11 | 1989-06-13 | Pfizer, Inc. | Process for preparing sertraline intermediates |
| US4777288A (en) * | 1987-06-11 | 1988-10-11 | Pfizer Inc. | Process for preparing a 4,4-diphenylbutanoic acid derivative |
| FR2623802B1 (fr) * | 1987-11-26 | 1990-05-04 | Lucien Laboratoires | Derives d'amino-4 trifluoromethyl-1 tetralines. leur preparation et leur application en therapeutique |
| US4855500A (en) * | 1988-05-04 | 1989-08-08 | Pfizer Inc. | Process for preparing a ketimine |
| FR2632633B1 (fr) * | 1988-06-08 | 1991-04-05 | Delalande Sa | Procede de preparation de 4-aryl-1-tetralones |
| US4981870A (en) * | 1989-03-07 | 1991-01-01 | Pfizer Inc. | Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants |
| US4940731A (en) * | 1989-08-30 | 1990-07-10 | Pfizer Inc. | Method of treating premature ejaculation using sertraline |
| EP0415612B1 (en) * | 1989-08-30 | 1993-11-10 | Pfizer Inc. | Use of sertraline for the treatment of chemical dependencies |
| US5130338A (en) * | 1989-08-30 | 1992-07-14 | Pfizer Inc. | Method of treating chemical dependencies using sertraline |
| US4962128A (en) * | 1989-11-02 | 1990-10-09 | Pfizer Inc. | Method of treating anxiety-related disorders using sertraline |
| FR2665443B1 (fr) * | 1990-08-03 | 1992-11-06 | Lucien Laboratoires | Derives d'amino-4-methyl-1-tetralines, leur preparation et leur application en therapeutique. |
| US5082970A (en) * | 1991-03-06 | 1992-01-21 | Pfizer Inc. | Process for recycling amine isomer |
| GB9114947D0 (en) * | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline |
| GB9114948D0 (en) * | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| US5196607A (en) * | 1992-02-14 | 1993-03-23 | Pfizer Inc. | Process for preparing ketone enantiomer |
| US5248699A (en) * | 1992-08-13 | 1993-09-28 | Pfizer Inc. | Sertraline polymorph |
| US5288916A (en) | 1993-03-25 | 1994-02-22 | Bend Research, Inc. | Enantiomeric resolution of 4-(3,4-dichlorophenyl)-3,4-dihydro-1(2H)-naphthalenone |
| CA2176500C (en) * | 1993-11-30 | 1999-09-28 | George J. Quallich | Process for preparing a chiral tetralone |
| US5597826A (en) | 1994-09-14 | 1997-01-28 | Pfizer Inc. | Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist |
| US6455736B1 (en) | 1994-12-16 | 2002-09-24 | Uop Llc | Process for preparation of pharmaceutically desired sertraline and sertraline analogs |
| US6410794B1 (en) | 1994-12-16 | 2002-06-25 | Uop Llc | Process for preparation of pharmaceutically desired chiral tetralone from tetralones |
| AU5966196A (en) * | 1995-06-08 | 1997-01-09 | Eli Lilly And Company | Methods of treating cold and allergic rhinitis |
| US6548084B2 (en) * | 1995-07-20 | 2003-04-15 | Smithkline Beecham Plc | Controlled release compositions |
| WO1997006792A1 (en) * | 1995-08-16 | 1997-02-27 | Eli Lilly And Company | Potentiation of serotonin response |
| US5734083A (en) * | 1996-05-17 | 1998-03-31 | Torcan Chemical Ltd. | Sertraline polymorph |
| HU222341B1 (hu) * | 1996-12-18 | 2003-06-28 | Richter Gedeon Vegyészeti Gyár Rt. | Eljárás sertralin előállítására és az eljárásban alkalmazott intermedier |
| TW526195B (en) * | 1997-06-10 | 2003-04-01 | Novartis Ag | Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and their use |
| US20030133974A1 (en) * | 1997-07-01 | 2003-07-17 | Curatolo William John | Encapsulated solution dosage forms of sertraline |
| US20040208926A1 (en) * | 1997-07-01 | 2004-10-21 | Pfizer Inc | Solubilized sertraline compositions |
| NZ513456A (en) * | 1997-07-01 | 2003-02-28 | Pfizer | Sertraline acetate, L-lactate and L-aspartate, processes for their preparation and their uses in psychotic disorders |
| DE69713353D1 (de) * | 1997-12-11 | 2002-07-18 | Torcan Chemical Ltd | Sertralin-Polymorph mit verbesserter Wasserlöslichkeit |
| IN191358B (bs) | 1998-01-16 | 2003-11-29 | Pfizer Prod Inc | |
| WO1999046233A1 (en) * | 1998-03-09 | 1999-09-16 | Sumika Fine Chemicals Co., Ltd. | Benzyl alcohol derivatives |
| EP1064250B1 (en) * | 1998-03-18 | 2004-04-21 | Ciba SC Holding AG | Process for the cis-selective catalytic hydrogenation of cyclohexylidenamines |
| FR2777000B1 (fr) * | 1998-04-01 | 2002-09-27 | Catalys | Procede de preparation de la sertraline racemique |
| ATE228119T1 (de) * | 1998-04-15 | 2002-12-15 | Pfizer Prod Inc | Heterocyclische carboxamide |
| US6054614A (en) * | 1998-04-23 | 2000-04-25 | Ciba Specialty Chemicals Corporation | Process for the preparation of tetralone imines for the preparation of active pharmaceutical compounds |
| HU226424B1 (en) * | 1998-05-05 | 2008-12-29 | Egis Gyogyszergyar Nyrt | Process for producing enantiomer mixture for preparation of sertraline |
| HU226423B1 (en) * | 1998-05-05 | 2008-12-29 | Egis Gyogyszergyar Nyrt | Process for producing a 1(2h)-naphtalene-1-ylidene derivative |
| IN182588B (bs) * | 1998-05-12 | 1999-05-08 | Sun Pharmaceutical Ind Ltd | |
| DE19830201A1 (de) * | 1998-07-07 | 2000-01-13 | Boehringer Ingelheim Pharma | Mittel mit antidepressiver Wirkung |
| AP2001002119A0 (en) * | 1998-10-13 | 2001-03-22 | Pfizer Prod Inc | Sertraline oral concentrate. |
| US6727283B2 (en) | 1998-10-13 | 2004-04-27 | Pfizer Inc. | Sertraline oral concentrate |
| IL132500A0 (en) | 1998-10-29 | 2001-03-19 | Pfizer Prod Inc | Stereoselective microbial reduction of a racemic tetralone |
| AU1031500A (en) * | 1998-11-03 | 2000-05-22 | Dandy A/S | Sucrose fatty acid esters for use as increased release of active ingredients |
| US6518284B2 (en) * | 1998-11-18 | 2003-02-11 | Faes, Fabrica Espanola De Productos Quimicos Y Farmaceuticos S.A. | 4-substituted piperidines |
| EP1637516A1 (en) * | 1998-11-27 | 2006-03-22 | Teva Pharmaceutical Industries Ltd | Sertraline hydrochloride polymorphs |
| AU1633600A (en) * | 1998-11-27 | 2000-06-19 | Teva Pharmaceutical Industries Ltd. | Sertraline hydrochloride polymorphs |
| US6500987B1 (en) * | 1998-11-27 | 2002-12-31 | Teva Pharmaceutical Industries Ltd. | Sertraline hydrochloride polymorphs |
| AU2315400A (en) * | 1999-03-01 | 2000-09-21 | Middleton, Donald Stuart | 1,2,3,4-tetrahydro-1-naphthalenamine compounds useful in therapy |
| US6245782B1 (en) | 1999-05-17 | 2001-06-12 | Heartdrug Research L.L.C. | Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors |
| YU32700A (sh) | 1999-06-09 | 2002-03-18 | Pfizer Products Inc. | Postupak za dobijanje sertralina iz hiralnog tetralona |
| DK1200387T3 (da) * | 1999-07-29 | 2004-07-19 | Ciba Sc Holding Ag | Fremgangsmåde til den cis-selektive katalytiske hydrogenering af cyclohexylidenaminer |
| US6495721B1 (en) * | 1999-08-09 | 2002-12-17 | Teva Pharmaceutical Industries Ltd. | Sertraline hydrochloride Form II and methods for the preparation thereof |
| IN185109B (bs) * | 1999-09-01 | 2000-11-18 | Torrent Pharmaceuticals Ltd | |
| DK174219B1 (da) * | 1999-10-27 | 2002-09-30 | Gea Farmaceutisk Fabrik As | Forbedret syntese af racemisk sertralin |
| US20050119351A1 (en) * | 1999-10-29 | 2005-06-02 | Van Der Schaaf Paul A. | Polymorphic forms of sertraline hydrochloride |
| US7442838B2 (en) * | 1999-10-29 | 2008-10-28 | Ciba Specialty Chemicals Corp. | Polymorphic forms of sertraline hydrochloride |
| TWI260315B (en) * | 1999-10-29 | 2006-08-21 | Ciba Sc Holding Ag | Polymorphic forms of sertraline hydrochloride |
| DE60021410T2 (de) | 1999-11-16 | 2006-05-24 | Ciba Speciality Chemicals Holding Inc. | Verfahren zur herstellung von ketiminen |
| JP2003514794A (ja) | 1999-11-16 | 2003-04-22 | チバ スペシャルティ ケミカルズ ホールディング インコーポレーテッド | ケトイミンの調製方法 |
| US6380200B1 (en) | 1999-12-07 | 2002-04-30 | Pfizer, Inc. | Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications |
| SK8872002A3 (en) * | 1999-12-21 | 2002-12-03 | Teva Pharma | Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them |
| EP1239839A2 (en) | 1999-12-23 | 2002-09-18 | Pfizer Products Inc. | Hydrogel-driven layered drug dosage form comprising sertraline |
| IN187170B (bs) | 2000-01-04 | 2002-02-23 | Sun Pharmaceutical Ind Ltd | |
| AU4363401A (en) * | 2000-03-14 | 2001-09-24 | Teva Pharma | Novel process for preparing (+)-cis-sertraline |
| WO2001078721A1 (en) * | 2000-04-13 | 2001-10-25 | Mayo Foundation For Medical Education And Research | Aβ42 LOWERING AGENTS |
| IN192343B (bs) * | 2000-05-26 | 2004-04-10 | Ranbaxy Lab Ltd | |
| ATE324365T1 (de) * | 2000-08-31 | 2006-05-15 | Pfizer | Phenoxyphenylheterozyklen als serotonin- wiederaufnahmehemmer |
| US6630504B2 (en) | 2000-08-31 | 2003-10-07 | Pfizer Inc. | Phenoxyphenylheterocyclyl derivatives as SSRIs |
| US6482440B2 (en) | 2000-09-21 | 2002-11-19 | Phase 2 Discovery, Inc. | Long acting antidepressant microparticles |
| US6645946B1 (en) | 2001-03-27 | 2003-11-11 | Pro-Pharmaceuticals, Inc. | Delivery of a therapeutic agent in a formulation for reduced toxicity |
| US7067700B2 (en) * | 2001-05-31 | 2006-06-27 | Fermion Oy | Process for preparing sertraline hydrochloride polymorphic form II |
| US6723878B2 (en) | 2001-06-15 | 2004-04-20 | Orion Corporation Fermion | Method for preparing sertraline |
| EP1401800A1 (en) * | 2001-06-15 | 2004-03-31 | Orion Corporation Fermion | A novel process for the preparation of (is-cis) -4-(3, 4-dichlorophenyl) -1, 2, 3, 4 - tetrahydro-n-methyl-1-naphthalenamine |
| CA2462903C (en) * | 2001-10-12 | 2011-09-20 | Serenix Pharmaceuticals, Llc | Beta-lactamyl vasopressin v1a antagonists |
| EP2316469A1 (en) | 2002-02-22 | 2011-05-04 | Shire LLC | Delivery system and methods for protecting and administering dextroamphetamine |
| WO2003093217A1 (en) * | 2002-04-29 | 2003-11-13 | Teva Pharmaceutical Industries Ltd. | Process for preparation of polymorphic form ii of sertraline hydrochloride, pharmaceutical formulations and methods of administration thereof |
| WO2004011413A1 (en) * | 2002-07-29 | 2004-02-05 | Cipla Limited | Sertraline |
| BR0316032A (pt) * | 2002-11-07 | 2005-09-27 | Torrent Pharmaceuticals Ltd | Processo para a preparação da forma polimórfica do cloridrato de sertralina |
| US20040131672A1 (en) * | 2003-01-07 | 2004-07-08 | Nilobon Podhipleux | Direct compression pharmaceutical composition containing a pharmaceutically active ingredient with poor flowing properties |
| EP1603548A4 (en) * | 2003-02-05 | 2007-10-10 | Myriad Genetics Inc | METHOD AND COMPOSITION FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES |
| WO2004087732A2 (en) * | 2003-03-11 | 2004-10-14 | Sun Pharmaceutical Industries Limited | Process for the preparation of (1s, 4s)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-naphthylamine |
| TW200503991A (en) * | 2003-04-14 | 2005-02-01 | Teva Pharma | Hydrogenation of imine intermediates of sertraline with catalysts |
| JP2007502329A (ja) * | 2003-05-23 | 2007-02-08 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | セルトラリン組成物 |
| US20050070577A1 (en) * | 2003-07-03 | 2005-03-31 | Pfizer Inc. | Compositions containing a serotonin selective reuptake inhibitor and a 5-HT2A receptor antagonist |
| WO2005065069A2 (en) * | 2003-07-11 | 2005-07-21 | Myriad Genetics, Inc. | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease |
| EP1646605A1 (en) * | 2003-07-15 | 2006-04-19 | Recordati Industria Chimica e Farmaceutica S.p.A. | Sertraline hydrochloride form ii and methods for the preparation thereof |
| EP1648854A1 (en) * | 2003-07-15 | 2006-04-26 | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a. | Methods for preparing sertraline hydrochloride polymorphs |
| HU227495B1 (en) * | 2003-07-21 | 2011-07-28 | Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag | Process for producing of imine intermediate |
| CA2537804A1 (en) * | 2003-09-05 | 2005-03-17 | Teva Pharmaceutical Industries Ltd | A recycling process for preparing sertraline |
| BRPI0414347A (pt) * | 2003-09-12 | 2006-11-07 | Warner Lambert Co | associação compreendendo um ligando de alfa-2-delta e um ssri e/ou snri para tratamento de depressão e distúrbios da ansiedade |
| DE602004024317D1 (de) | 2003-09-12 | 2010-01-07 | Pfizer | Kombinationen aus alpha-2-delta liganden und serotonin / noradrenalin-wiederaufnahmehemmern |
| PL1668014T3 (pl) * | 2003-09-17 | 2009-06-30 | Janssen Pharmaceutica Nv | Skondensowane związki heterocykliczne jako modulatory receptora serotoninowego |
| ATE469119T1 (de) * | 2003-11-04 | 2010-06-15 | Cipla Ltd | Verfahren zur herstellung von polymorphen von sertralin hydrochlorid |
| DE602004028150D1 (de) * | 2003-11-26 | 2010-08-26 | Pfizer Prod Inc | Aminopyrazolderivate als gsk-3-inhibitoren |
| US20050250803A1 (en) * | 2003-11-26 | 2005-11-10 | Pfizer Inc | Combination of dopamine agonists and monoamine reuptake inhibitors |
| DK1691811T3 (da) | 2003-12-11 | 2014-10-20 | Sunovion Pharmaceuticals Inc | Kombination af et sedativ og en neurotransmittermodulator og fremgangsmåder til forbedring af søvnkvaliteten og behandling af depression |
| WO2006001877A2 (en) * | 2004-04-13 | 2006-01-05 | Myriad Genetics, Inc. | Combination treatment for neurodegenerative disorders comprising r-flurbiprofen |
| US20050233010A1 (en) * | 2004-04-19 | 2005-10-20 | Satow Philip M | Lithium combinations, and uses related thereto |
| EP1742535A4 (en) * | 2004-05-06 | 2008-10-15 | Cydex Pharmaceuticals Inc | MASTER TASTE PREPARATIONS CONTAINING SERTRALINE AND SULFOALKYLETHER CYCLODEXTRIN |
| AR049401A1 (es) | 2004-06-18 | 2006-07-26 | Novartis Ag | Aza-biciclononanos |
| GB0415746D0 (en) | 2004-07-14 | 2004-08-18 | Novartis Ag | Organic compounds |
| WO2006020850A2 (en) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Pharmaceutical composition and method for treating neurodegenerative disorders |
| BRPI0514303A (pt) * | 2004-08-11 | 2008-06-10 | Myriad Genetics Inc | composição farmacêutica e método para tratar distúrbios neurodegenerativos |
| WO2006020852A2 (en) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Pharmaceutical composition and method for treating neurodegenerative disorders |
| TW200640836A (en) * | 2005-02-23 | 2006-12-01 | Teva Pharma | Processes for preparing sertraline |
| WO2006102283A2 (en) | 2005-03-22 | 2006-09-28 | Azevan Pharmaceuticals, Inc. | Beta-lactamylalkanoic acids for treating premenstrual disorders |
| JP2006265169A (ja) * | 2005-03-24 | 2006-10-05 | Tokuyama Corp | アルキリデンコハク酸化合物の製造方法 |
| GB0507090D0 (en) * | 2005-04-07 | 2005-05-11 | Sandoz Ag | Process for preparing polymorphic form ll of sertraline hydrochloride |
| GB0507298D0 (en) | 2005-04-11 | 2005-05-18 | Novartis Ag | Organic compounds |
| JP2008538581A (ja) * | 2005-04-22 | 2008-10-30 | ワイス | ｛［（２ｒ）−７−（２，６−ジクロロフェニル）−５−フルオロ−２，３−ジヒドロ−１−ベンゾフラン−２−イル］メチル｝アミン塩酸塩の結晶形態 |
| JP2008538577A (ja) * | 2005-04-22 | 2008-10-30 | ワイス | ジヒドロベンゾフラン誘導体およびその使用 |
| PE20061298A1 (es) | 2005-04-22 | 2006-12-24 | Wyeth Corp | Compuestos derivados de dihidrobenzofurano como agonistas del receptor de serotonina 5-ht2c |
| RU2007139541A (ru) * | 2005-04-22 | 2009-05-27 | Вайет (Us) | Производные хромана и хромена и их применение |
| WO2006116151A1 (en) * | 2005-04-22 | 2006-11-02 | Wyeth | Benzofuranyl alkanamine derivatives and uses thereof as 5-ht2c agonists |
| EP1885683A2 (en) * | 2005-06-03 | 2008-02-13 | Hetero Drugs Limited | A highly stereoselective synthesis of sertraline |
| US20070100165A1 (en) * | 2005-06-09 | 2007-05-03 | Ronen Borochovitz | Process for preparation of sertraline hydrochloride form I |
| RU2408368C2 (ru) * | 2005-06-27 | 2011-01-10 | Биовэйл Лэборэториз Интернэшнл С.Р.Л. | Препараты соли бупропиона с модифицированным высвобождением |
| AU2006269231A1 (en) | 2005-07-08 | 2007-01-18 | Braincells, Inc. | Methods for identifying agents and conditions that modulate neurogenesis |
| US20070015832A1 (en) * | 2005-07-14 | 2007-01-18 | Myriad Genetics, Incorporated | Methods of treating overactive bladder and urinary incontinence |
| EP1910346B1 (en) * | 2005-07-19 | 2019-02-27 | Azevan Pharmaceuticals, Inc. | Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonist |
| US7598255B2 (en) * | 2005-08-04 | 2009-10-06 | Janssen Pharmaceutica Nv | Pyrimidine compounds as serotonin receptor modulators |
| EP1940389A2 (en) | 2005-10-21 | 2008-07-09 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| JP2009513672A (ja) | 2005-10-31 | 2009-04-02 | ブレインセルス，インコーポレイティド | 神経発生のｇａｂａ受容体媒介調節 |
| GB0525673D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
| GB0525672D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
| KR101381768B1 (ko) * | 2006-01-06 | 2014-04-07 | 선오비온 파마슈티컬스 인코포레이티드 | 테트랄론-기재 모노아민 재흡수 저해제 |
| EP1858838A1 (en) * | 2006-01-23 | 2007-11-28 | Teva Pharmaceutical Industries Ltd. | A recycling process for preparing sertraline |
| FR2912057B1 (fr) * | 2007-02-07 | 2009-04-17 | Sanofi Aventis Sa | Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| CN101410112A (zh) * | 2006-03-24 | 2009-04-15 | 惠氏公司 | 治疗抑郁症的新治疗组合 |
| WO2007119247A2 (en) * | 2006-04-17 | 2007-10-25 | Unichem Laboratories Limited | Improved manufacturing procedure for the preparation of polymorphic form ii of cis-(1s)-n-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthleneamine hydrochloride (sertraline hydrochloride) |
| TR200808115T1 (tr) * | 2006-04-28 | 2009-03-23 | Sandoz Ag | 4(S,R)-(3,4-diklorofenil)-3,4-dihidro-l(2H)-naftalin-l-ilid n]metilamin'ın Hazırlanması için Proses.@ |
| US7858611B2 (en) * | 2006-05-09 | 2010-12-28 | Braincells Inc. | Neurogenesis by modulating angiotensin |
| CA2651862A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
| EP2382975A3 (en) | 2006-05-09 | 2012-02-29 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| US7518019B2 (en) * | 2006-06-01 | 2009-04-14 | Hetero Drugs Limited | Processes for preparing sertraline hydrochloride crystalline forms |
| US20100279990A1 (en) * | 2006-06-13 | 2010-11-04 | Ramot At Tel-Aviv University Ltd. | Antiproliferative compounds, compositions and methods of use |
| US7893053B2 (en) * | 2006-06-16 | 2011-02-22 | Theracos, Inc. | Treating psychological conditions using muscarinic receptor M1 antagonists |
| EP2046119A2 (en) * | 2006-07-07 | 2009-04-15 | Myriad Genetics, Inc. | Treatment of psychiatric disorders |
| TW200817003A (en) * | 2006-07-31 | 2008-04-16 | Sanofi Aventis | Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor |
| US20060257475A1 (en) * | 2006-08-17 | 2006-11-16 | Boehringer Ingelheim International Gmbh | Stable Sertraline Hydrochloride Formulation and Method |
| KR20090064418A (ko) | 2006-09-08 | 2009-06-18 | 브레인셀즈 인코퍼레이션 | 4-아실아미노피리딘 유도체 포함 조합물 |
| WO2008034032A2 (en) * | 2006-09-14 | 2008-03-20 | Azevan Pharmaceuticals, Inc. | Beta-lactam cannabinoid receptor modulators |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| FR2909376A1 (fr) * | 2006-11-30 | 2008-06-06 | Cerep Sa | Procedes de preparation de la desmethulsertraline ou d'un de ses sels pharmaceutiquement acceptables |
| US20080167363A1 (en) * | 2006-12-28 | 2008-07-10 | Braincells, Inc | Modulation of Neurogenesis By Melatoninergic Agents |
| EP2125017A2 (en) * | 2007-01-11 | 2009-12-02 | Braincells, Inc. | Modulation of neurogenesis with use of modafinil |
| CA2594198A1 (en) * | 2007-07-20 | 2009-01-20 | Apotex Pharmachem Inc. | A novel process for the preparation of sertraline hydrochloride form ii |
| US20090062399A1 (en) * | 2007-08-29 | 2009-03-05 | Protia, Llc | Deuterium-enriched sertraline |
| EP2288345B1 (en) | 2008-04-18 | 2015-06-10 | University College Dublin National University Of Ireland, Dublin | Psycho-pharmaceuticals |
| EP2291181B9 (en) | 2008-04-18 | 2013-09-11 | University College Dublin National University Of Ireland, Dublin | Captodiamine for the treatment of depression symptoms |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| US9260413B2 (en) * | 2010-03-04 | 2016-02-16 | Merck Sharp & Dohme Corp. | Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders |
| EP2380595A1 (en) | 2010-04-19 | 2011-10-26 | Nlife Therapeutics S.L. | Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types |
| WO2011163231A2 (en) | 2010-06-21 | 2011-12-29 | Theracos, Inc. | Combination therapy for the treatment of diabetes |
| CN107007596A (zh) | 2010-07-01 | 2017-08-04 | 阿泽凡药物公司 | 用于治疗创伤后应激障碍的方法 |
| PH12013501900A1 (en) | 2011-03-17 | 2017-08-23 | Lupin Ltd | Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor |
| KR101340270B1 (ko) * | 2011-11-10 | 2013-12-10 | 보령제약 주식회사 | (+)-시스-서트랄린의 선택적인 제조방법 |
| WO2014060384A1 (en) * | 2012-10-18 | 2014-04-24 | F. Hoffmann-La Roche Ag | Ethynyl derivatives as modulators of mglur5 receptor activity |
| WO2015148962A1 (en) | 2014-03-28 | 2015-10-01 | Azevan Pharmaceuticals, Inc. | Compositions and methods for treating neurodegenerative diseases |
| WO2015193921A1 (en) | 2014-06-20 | 2015-12-23 | Council Of Scientific And Industrial Research | An organocatalytic asymmetric synthesis of antidepressants |
| EP3180340B1 (en) * | 2014-08-11 | 2018-10-10 | Hydra Biosciences, Inc. | Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives |
| JP6667092B2 (ja) * | 2014-08-11 | 2020-03-18 | ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ， ＬＬＣ | ピロロ［３，２−ｄ］ピリミジン−２，４（３Ｈ，５Ｈ）−ジオン誘導体 |
| EP3180337B1 (en) * | 2014-08-11 | 2018-10-10 | Hydra Biosciences, Inc. | Pyrido[3,4-d]pyrimidine-2,4(1h,3h)-dione derivatives |
| WO2016023832A1 (en) * | 2014-08-11 | 2016-02-18 | Hydra Biosciences, Inc. | Thieno- and furo[2,3-d]pyrimidine-2,4[1h,3h]-dione derivatives as trpc5 modulators for the treatment of neuropsychiatric disorders |
| AU2016326442B2 (en) | 2015-09-21 | 2022-05-12 | S.C. Johnson & Son, Inc. | System for mixing and dispensing |
| JP2020534274A (ja) | 2017-09-15 | 2020-11-26 | アゼヴァン ファーマシューティカルズ，インコーポレイテッド | 脳損傷を治療するための組成物及び方法 |
| WO2020043716A1 (en) | 2018-08-27 | 2020-03-05 | Katholieke Universiteit Leuven | Pharmacological targeting of de novo serine/glycine synthesis |
| GB2630572A (en) | 2023-05-29 | 2024-12-04 | Novumgen Ltd | An orally disintegrating tablet of sertraline and its process of preparation |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2887509A (en) * | 1956-11-05 | 1959-05-19 | Lilly Co Eli | Hydroxybenzoyl benzoate salt of beta-(o-chlorophenyl)-beta-hydroxyethyl isopropylamine |
| US3704323A (en) * | 1969-12-23 | 1972-11-28 | Squibb & Sons Inc | Indane derivatives |
| US4029731A (en) * | 1974-11-06 | 1977-06-14 | Pfizer Inc. | Aminophenyltetralin compounds |
| US4045488A (en) * | 1974-11-06 | 1977-08-30 | Pfizer Inc. | Aminophenyltetralin compounds |
-
1979
- 1979-11-01 US US06/090,240 patent/US4536518A/en not_active Expired - Lifetime
-
1980
- 1980-09-18 DK DK395280A patent/DK153390C/da active
- 1980-09-27 IN IN699/DEL/80A patent/IN159643B/en unknown
- 1980-10-27 MX MX809122U patent/MX5980E/es unknown
- 1980-10-28 EP EP80303809A patent/EP0030081B1/en not_active Expired
- 1980-10-28 PH PH24780A patent/PH17319A/en unknown
- 1980-10-28 SU SU802999197A patent/SU1014467A3/ru active
- 1980-10-28 DE DE8080303809T patent/DE3062225D1/de not_active Expired
- 1980-10-28 UA UA2999197A patent/UA6301A1/uk unknown
- 1980-10-28 DE DE1997175012 patent/DE19775012I2/de active Active
- 1980-10-28 AT AT80303809T patent/ATE2668T1/de active
- 1980-10-28 UA UA3325759A patent/UA6311A1/uk unknown
- 1980-10-28 HU HU802601A patent/HU182224B/hu unknown
- 1980-10-29 CS CS807314A patent/CS238609B2/cs unknown
- 1980-10-29 EG EG666/80A patent/EG15527A/xx active
- 1980-10-30 CA CA363,568A patent/CA1130815A/en not_active Expired
- 1980-10-30 IL IL61374A patent/IL61374A/xx unknown
- 1980-10-30 DD DD80224840A patent/DD155615A5/de unknown
- 1980-10-30 DD DD80240118A patent/DD203045A5/de unknown
- 1980-10-30 NZ NZ195407A patent/NZ195407A/en unknown
- 1980-10-30 FI FI803398A patent/FI68806C/fi not_active IP Right Cessation
- 1980-10-30 GR GR63247A patent/GR70781B/el unknown
- 1980-10-31 KR KR1019800004176A patent/KR840002001B1/ko not_active Expired
- 1980-10-31 ES ES496443A patent/ES496443A0/es active Granted
- 1980-10-31 PT PT72004A patent/PT72004B/pt unknown
- 1980-10-31 YU YU2798/80A patent/YU41951B/xx unknown
- 1980-10-31 AU AU63897/80A patent/AU517357B2/en not_active Expired
- 1980-10-31 JP JP55153698A patent/JPS605584B2/ja not_active Expired
- 1980-10-31 IE IE2259/80A patent/IE50395B1/en not_active IP Right Cessation
- 1980-10-31 NO NO803258A patent/NO148996C/no unknown
- 1980-10-31 ZA ZA00806726A patent/ZA806726B/xx unknown
- 1980-10-31 SI SI8012798A patent/SI8012798A8/sl unknown
-
1981
- 1981-08-28 SU SU813325759A patent/SU1034602A3/ru active
- 1981-11-05 ES ES506892A patent/ES8207123A1/es not_active Expired
- 1981-11-11 CS CS818297A patent/CS238617B2/cs unknown
- 1981-11-11 CS CS818298A patent/CS238618B2/cs unknown
-
1983
- 1983-03-21 SI SI8310672A patent/SI8310672A8/sl unknown
- 1983-03-21 YU YU672/83A patent/YU42846B/xx unknown
-
1984
- 1984-01-20 IN IN060/DEL/84A patent/IN159644B/en unknown
- 1984-06-01 KR KR1019840003057A patent/KR840002000B1/ko not_active Expired
- 1984-08-13 SG SG565/84A patent/SG56584G/en unknown
- 1984-11-01 HK HK822/84A patent/HK82284A/en not_active IP Right Cessation
-
1985
- 1985-12-30 MY MY326/85A patent/MY8500326A/xx unknown
-
1991
- 1991-11-22 CS CS913542A patent/CS354291A3/cs unknown
-
1992
- 1992-03-16 BG BG096071A patent/BG60333B2/bg unknown
-
1993
- 1993-02-18 HR HR930199A patent/HRP930199B1/xx not_active IP Right Cessation
- 1993-06-24 LU LU88330C patent/LU88330I2/fr unknown
- 1993-11-15 LV LV931228A patent/LV5457A3/xx unknown
- 1993-11-15 LV LV931227A patent/LV5456A3/xx unknown
- 1993-12-30 HR HRP-672/83A patent/HRP931527B1/xx not_active IP Right Cessation
-
1994
- 1994-08-31 NL NL940018C patent/NL940018I1/nl unknown
-
1996
- 1996-09-24 NO NO1996011C patent/NO1996011I1/no unknown
-
1997
- 1997-03-28 BA BA970149A patent/BA97149B1/bs active
- 1997-03-28 BA BA970150A patent/BA97150B1/bs active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CS238609B2 (en) | Production method of new derivatives cis-phenyl-1,2,3,4-tetrahydro-1-naphthalene-amines | |
| EP0028901B1 (en) | Antidepressant derivatives of trans-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine and pharmaceutical compositions thereof | |
| US4476136A (en) | Aminomethyl-5 oxazolidinic derivatives and therapeutic use thereof | |
| US3637740A (en) | Aminobenzocycloalkane compounds | |
| US5801201A (en) | 1-phenyl-2-dimenthylaminomethyl-cyclohexan-1-ol compounds as pharmaceutical active ingredients | |
| JP2776919B2 (ja) | フルオキセチン類似体 | |
| DK166018B (da) | N-oe2-(4-fluorphenyl)-1-methyl)-ethyl-n-methyl-n-propynylamin, isomere og salte deraf, deres fremstilling og farmaceutiske praeparater indeholdende dem | |
| CS225850B2 (en) | Process for preparing new r,r-n-(2-phenyl-2-hydroxyethyl)-1-methyl-3-phenylpropylamines | |
| HU211124A9 (en) | Therapeutic agents | |
| DK166878B (da) | Fluorallylaminer og pharmakologisk acceptable syreadditionssalte deraf samt pharmaceutisk praeparat indeholdende disse forbindelser | |
| KR840002020B1 (ko) | 트랜스-4-페닐-1, 2, 3, 4-테트라하이드로-1-나프탈렌아민 유도체의 제조방법 | |
| US3312733A (en) | Optically active naphthylethanolamines and the salts thereof | |
| JPS62108869A (ja) | ド−パミン−β−ヒドロキシラ−ゼ抑制物質 | |
| JPS624250A (ja) | ベンズ三置換−２−アミノテトラリン | |
| PL129248B1 (en) | Method of preparation of novel cis isomer derivatives of 4-phenyl-1,2,3,4-tetrahydro-1-naphtaleneamine | |
| PL130600B1 (en) | Process for preparing novel cis-isomer derivatives of 4-phenyl-1,2,3,4-tetrahydro-1-naphtalenamine | |
| BE535964A (bs) |